Skip to main content

Safety and Tolerability

7
Pipeline Programs
6
Companies
7
Clinical Trials
0
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
7
0
0
0
0
0
Early DiscoveryClinical DevelopmentMarket

Competitive Landscape

6 companies ranked by most advanced pipeline stage

Alumis
AlumisSOUTH SAN FRANCISCO, CA
2 programs
2
A-005Phase 11 trial
Experimental drug: ESK-001Phase 11 trial
Active Trials
NCT07442149Completed135Est. Dec 2024
NCT05431634Completed49Est. Dec 2022
MerLion Pharmaceuticals
MerLion PharmaceuticalsGermany - Berlin
1 program
1
Finafloxacin 800 mgPhase 11 trial
Active Trials
NCT01907867Completed18Est. Feb 2012
Galecto Biotech
Galecto BiotechDenmark - Copenhagen
1 program
1
GB1211Phase 11 trial
Active Trials
NCT03809052Completed78Est. Jun 2019
Gabather
GabatherSweden - Södertälje
1 program
1
GT-002Phase 11 trial
Active Trials
NCT03817346Completed32Est. May 2019
MDI Therapeutics
1 program
1
MDI-2517Phase 11 trial
Active Trials
NCT06453824Completed48Est. Nov 2024
Modus Therapeutics
Modus TherapeuticsSweden - Stockholm
1 program
1
SevuparinPhase 11 trial
Active Trials
NCT03853421Completed24Est. May 2019

Trial Timeline

Clinical trial activity over time

2021
2022
2023
2024
2025
2026
MDI TherapeuticsMDI-2517
AlumisA-005
AlumisExperimental drug: ESK-001
Modus TherapeuticsSevuparin
Galecto BiotechGB1211
GabatherGT-002
MerLion PharmaceuticalsFinafloxacin 800 mg

Clinical Trials (7)

Total enrollment: 384 patients across 7 trials

NCT06453824MDI TherapeuticsMDI-2517

SAD Evaluation of Safety, Tolerability, PK, and PD of MDI-2517 in Healthy Participants

Start: May 2024Est. completion: Nov 202448 patients
Phase 1Completed
NCT07442149AlumisA-005

An Investigational Study to Evaluate the Safety and Tolerability of Single and Multiple Ascending Doses of A-005

Start: Apr 2024Est. completion: Dec 2024135 patients
Phase 1Completed
NCT05431634AlumisExperimental drug: ESK-001

Multiple Dose Study to Determine Safety and Tolerability of ESK-001 in Healthy Participants

Start: May 2022Est. completion: Dec 202249 patients
Phase 1Completed
NCT03853421Modus TherapeuticsSevuparin

Placebo-controlled Study to Determine the Safety and Tolerability of Subcutaneous Doses of Sevuparin

Start: Feb 2019Est. completion: May 201924 patients
Phase 1Completed
NCT03809052Galecto BiotechGB1211

A First in Human Study to Evaluate the Safety, Tolerability and PK of GB1211 in Healthy Subjects

Start: Jan 2019Est. completion: Jun 201978 patients
Phase 1Completed
NCT03817346GabatherGT-002

Study of Ascending Single Oral Dose of GT-002 in Healthy Volunteers

Start: Dec 2018Est. completion: May 201932 patients
Phase 1Completed
NCT01907867MerLion PharmaceuticalsFinafloxacin 800 mg

Pharmacokinetic Profile in Plasma and Epithelial Lining Fluid of Finafloxacin

Start: Jan 2012Est. completion: Feb 201218 patients
Phase 1Completed

Phase Legend

Preclinical— Lab & animal studies
Phase 1— Safety & dosing
Phase 2— Efficacy testing
Phase 3— Large-scale trials
On Market— Approved & available

Key Insights

6 companies competing in this space

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.